Amgen Vs Radius Health: Who Will Dominate Bone Density Market?
The market for osteoporosis drugs is heating up.
Radius Health (RDUS) unveiled strong clinical trial data for its once-daily bone formation drug abaloparatide, a rival to Eli Lilly’s (LLY) Forteo. Next year, biotech giant Amgen (AMGN) is slated to disclose results from a phase 3 study for its drug romosozumab. But according to Deutsche Bank analyst Robyn Karnauskas and team, a surveyed showed that romosozumab, which is administered via injection once a month, will likely be the first treatment choice among doctors, capturing 50% to 54% market share once it receives regulatory approval.
Hey, check out all the research scientist jobs. Post your resume today!
Radius Health (RDUS) unveiled strong clinical trial data for its once-daily bone formation drug abaloparatide, a rival to Eli Lilly’s (LLY) Forteo. Next year, biotech giant Amgen (AMGN) is slated to disclose results from a phase 3 study for its drug romosozumab. But according to Deutsche Bank analyst Robyn Karnauskas and team, a surveyed showed that romosozumab, which is administered via injection once a month, will likely be the first treatment choice among doctors, capturing 50% to 54% market share once it receives regulatory approval.
Hey, check out all the research scientist jobs. Post your resume today!